Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM) Clinical Trial

Official title:

Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01835730
• Other study ID #: PE0139-PT-CL-0001
• Status: Completed
• Phase: Phase 1
• First received: March 28, 2013
• Last updated: October 13, 2014
• Start date: April 2013
• Est. completion date: May 2014

Study information

• Verified date: October 2014
• Source: PhaseBio Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Willing and able to sign a written informed consent and follow all study-related procedures;

• Male and female subjects at least 18 years of age;

• Male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their dose of study drug;

• Body mass index =45 kg/m2;

• Diagnosed with T2DM and who is currently taking a stable daily dose of a basal insulin (Lantus) plus at least one oral antihyperglycemic agent at a stable dose for 3 months prior to screening.

Exclusion Criteria:

• Currently taking or have taken within 3 months prior to screening an approved or investigational GLP-1 analogue/agonist (e.g., Victoza®) or pramlintide;

• Currently taking or have routinely taken, within 3 months prior to screening , a short-acting insulin;

• Currently taking or have taken, within 3 months prior to screening, a long acting insulin other than Lantus®;

• Known allergy to, or serious adverse effect caused by an approved, or investigational insulin product or any of its components;

• Currently taking any of the following medications: thiazide or furosemide diuretics, beta-blockers, estrogens or other hormonal replacement therapy, or other chronic medications with known adverse effects on glucose tolerance levels unless the subject has been on stable doses of such agents for at least 2 months prior to screening and have no planned changes during the study period;

• History of recurrent severe hypoglycemia (more than 2 episodes within the last 6 months prior to randomization or hypoglycemic unawareness;

• Malignant disease defined as 1) any history of malignant melanoma or breast cancer and/or 2) history of other types of cancer within the last 5 years prior to screening;

• Unstable cardiovascular disease defined as one or more of the following: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to screening; History of or currently have New York Heart Association Class III-IV heart failure prior to screening; Uncontrolled/sustained hypertension; History or evidence of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT interval;

• Clinically significant renal and/or hepatic dysfunction;

• Absolute requirement for corticosteroids or have received systemic steroids within 3 months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical corticosteroids will be permitted;

• Pregnant or lactating female subjects;

• Known history of or active alcohol abuse or use of illicit drugs within 1 year prior to screening;

• Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies at V1;

• Participating in any other study and have received any other investigational medication or device within 30 days prior to Visit 1.

• Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus (T2DM)

Intervention

Drug:
• PE0139 Injection

• Placebo

Locations

Country	Name	City	State
United States	Pinnacle Research Group, LLC	Anniston	Alabama
United States	Palm Springs Research Institute	Hialeah	Florida
United States	Rainier Clinical Research	Renton	Washington

Sponsors (1)

Lead Sponsor	Collaborator
PhaseBio Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Vital Signs from baseline (Day 0 Pre-dose)	Safety will be evaluated by analyses of the change from baseline in vital signs.	Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28	Yes
Primary	Change in ECGs from baseline (Day -1)	Safety will be evaluated by analyses of the change from baseline in 12-lead ECG.	ECG Days 2 and 28	Yes
Primary	Change in Safety Labs from baseline (Pre-dose)	Safety will be evaluated by analyses of the safety laboratory parameters.	Safety Labs Days 0, 7 and 28	Yes
Primary	Incidence and severity of immunogenicity	Safety will be evaluated by the incidence and severity of immunogenicity.	Immunogenicity Days 0, 7, 14 and 28	Yes
Primary	Incidence and severity of adverse events including hypoglycemia	Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia.	As reported between Days -10 to 28	Yes
Secondary	Pharmacokinetic Profile	Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F)	Day 0, 1, 2, 3, 4, 5, 6, and 7	No
Secondary	Pharmacodynamic Response	To assess the pharmacodynamic response (time action profile) of various single doses of PE0139. Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM).	FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7	No